{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:37:48Z","timestamp":1774791468290,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103385","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T02:11:06Z","timestamp":1636423866000},"page":"103385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis"],"prefix":"10.1016","volume":"57","author":[{"given":"Bruno","family":"Brochet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Hupperts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Solari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Selmaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Valis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Rejdak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva K.","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nektaria","family":"Alexandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103385_bib0001","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1352458517726380","article-title":"Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis","volume":"24","author":"Afolabi","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103385_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11593310-000000000-00000","article-title":"Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study","volume":"32","author":"Ali","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.msard.2021.103385_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.msard.2021.103385_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103385_bib0005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103385_bib0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2019.03.022","article-title":"Teriflunomide real-world evidence: global differences in the phase 4 Teri-PRO study","volume":"31","author":"Coyle","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103385_bib0007","unstructured":"EMD Serono, I., 2019. MAVENCLAD Prescribing Information."},{"issue":"10","key":"10.1016\/j.msard.2021.103385_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185766","article-title":"Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)","volume":"12","author":"Fern\u00e1ndez","year":"2017","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.msard.2021.103385_bib0009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1756285616634247","article-title":"Therapy satisfaction and adherence in patients with relapsing\u2013remitting multiple sclerosis: the THEPA-MS survey","volume":"9","author":"Haase","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103385_bib0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40263-017-0444-x","article-title":"Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs","volume":"31","author":"Jongen","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103385_bib0011","unstructured":"Merck Europe B.V., 2021. MAVENCLAD Summary of Product Characteristics."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2021.103385_bib0012","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ene.12800","article-title":"Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice","volume":"22","author":"Oreja-Guevara","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103385_bib0013","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2021.103385_bib0014","article-title":"Epub ahead of print. Global, regional and national quality of life in patients with multiple sclerosis: a global systematic review and meta-analysis","author":"Pashazadeh Kan","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.msard.2021.103385_bib0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/1352458516657441","article-title":"Measuring treatment satisfaction in MS: is the Treatment Satisfaction Questionnaire for Medication fit for purpose?","volume":"23","author":"Vermersch","year":"2017","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:36:05Z","timestamp":1735576565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":15,"alternative-id":["S2211034821006520"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103385","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103385"}}